Sun Pharma announced on Wednesday that it plans to offer a drug to lower low-density lipoprotein (LDL) cholesterol.
The Mumbai-based pharmaceutical company said one of its wholly-owned subsidiaries wants to commercialise Bempedoic Acid, a first-in-class oral medication for lowering LDL cholesterol, in India. Brillo will be the brand name for the medicine when it is released. 

In comparison to currently existing lipid-lowering medications, the drug is a first-in-class drug with a novel mode of action. It is for those who have an inherited genetic abnormality that produces high cholesterol or who already have heart disease and have high cholesterol despite changing their lifestyle and taking a maximum tolerable dose of statins.

"In India, Sun Pharma is the market leader in cardiovascular therapy and a pioneer in lipid-lowering medication. Sun Pharma CEO – India Business Kirti Ganorkar said in a statement, "In line with our commitment to delivering unique medications, we are launching this first-in-class oral drug Brillo."

He noted that the medication offers a revolutionary therapy option that will help patients with heart disease control high LDL cholesterol, a problem that is developing at an alarming rate.

Health ministry launches training module on emergency life support

Ayushman Bharat: Health Wellness scheme on track in most states to achieve targets

Study finds Drug treatment for cataracts moves a step closer